| pubmed-article:16488992 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C1334091 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C0001430 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C0021853 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C0021118 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C0439232 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:16488992 | lifeskim:mentions | umls-concept:C1517945 | lld:lifeskim |
| pubmed-article:16488992 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16488992 | pubmed:dateCreated | 2006-2-20 | lld:pubmed |
| pubmed-article:16488992 | pubmed:abstractText | The potent growth-promoting activity of insulin-like growth factor-II (IGF-II) is highly regulated during development but frequently up-regulated in tumors. Increased expression of the normally monoallelic (paternally expressed) mouse (Igf2) and human (IGF2) genes modify progression of intestinal adenoma in the Apc(Min/+) mouse and correlate with a high relative risk of human colorectal cancer susceptibility, respectively. We examined the functional consequence of Igf2 allelic dosage (null, monoallelic, and biallelic) on intestinal adenoma development in the Apc(Min/+) by breeding with mice with either disruption of Igf2 paternal allele or H19 maternal allele and used these models to evaluate an IGF-II-specific therapeutic intervention. Increased allelic Igf2 expression led to elongation of intestinal crypts, increased adenoma growth independent of systemic growth, and increased adenoma nuclear beta-catenin staining. By introducing a transgene expressing a soluble form of the full-length IGF-II/mannose 6-phosphate receptor (sIGF2R) in the intestine, which acts as a specific inhibitor of IGF-II ligand bioavailability (ligand trap), we show rescue of the Igf2-dependent intestinal and adenoma phenotype. This evidence shows the functional potency of allelic dosage of an epigenetically regulated gene in cancer and supports the application of an IGF-II ligand-specific therapeutic intervention in colorectal cancer. | lld:pubmed |
| pubmed-article:16488992 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16488992 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16488992 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16488992 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16488992 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16488992 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16488992 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16488992 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16488992 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:16488992 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:16488992 | pubmed:author | pubmed-author:ZainaSilvioS | lld:pubmed |
| pubmed-article:16488992 | pubmed:author | pubmed-author:HassanA... | lld:pubmed |
| pubmed-article:16488992 | pubmed:author | pubmed-author:PignatelliMas... | lld:pubmed |
| pubmed-article:16488992 | pubmed:author | pubmed-author:BurnsJason... | lld:pubmed |
| pubmed-article:16488992 | pubmed:author | pubmed-author:HarperJamesJ | lld:pubmed |
| pubmed-article:16488992 | pubmed:author | pubmed-author:FoulstoneEmil... | lld:pubmed |
| pubmed-article:16488992 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16488992 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:16488992 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:16488992 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16488992 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16488992 | pubmed:pagination | 1940-8 | lld:pubmed |
| pubmed-article:16488992 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:meshHeading | pubmed-meshheading:16488992... | lld:pubmed |
| pubmed-article:16488992 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16488992 | pubmed:articleTitle | Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. | lld:pubmed |
| pubmed-article:16488992 | pubmed:affiliation | Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol, United Kingdom. | lld:pubmed |
| pubmed-article:16488992 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16488992 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:11789 | entrezgene:pubmed | pubmed-article:16488992 | lld:entrezgene |
| entrez-gene:14955 | entrezgene:pubmed | pubmed-article:16488992 | lld:entrezgene |
| entrez-gene:16002 | entrezgene:pubmed | pubmed-article:16488992 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16488992 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16488992 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16488992 | lld:pubmed |
